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Abstract: This study aims at clarifying the prognostic role of high-grade tumor budding (TB) in
pancreatic ductal adenocarcinoma (PDAC) with the first systematic review and meta-analysis on this
topic. Furthermore, we analyzed with a systematic review the relationship between TB and a recently
suggested TB-associated mechanism: the epithelial to mesenchymal transition (EMT). Analyzing a
total of 613 patients, 251 of them (40.9%) with high grade-TB, we found an increased risk of all-cause
mortality (RR, 1.46; 95% CI, 1.13–1.88, p = 0.004; HR, 2.65; 95% CI, 1.79–3.91; p < 0.0001) and of
recurrence (RR, 1.61; 95% CI, 1.05–2.47, p = 0.03) for PDAC patients with high-grade TB. Moreover,
we found that EMT is a central process in determining the presence of TB in PDAC. Thanks to this
meta-analysis, we demonstrate the potential clinical significance of high-grade TB for prognostic
stratification of PDAC. TB also shows a clear association with the process of EMT. Based on the results
of the present study, TB should be conveyed in pathology reports and taken into account by future
oncologic staging systems.
Keywords: budding; buds; epithelial to mesenchymal transition; EMT; pancreatic cancer
Cancers 2019, 11, 113; doi:10.3390/cancers11010113 www.mdpi.com/journal/cancers
Cancers 2019, 11, 113 2 of 11
1. Introduction
Pancreatic ductal adenocarcinoma (PDAC) is an aggressive tumor that represents the seventh
cause of death for cancer in the world, with an increasing tendency of incidence for the future [1–4].
Notably, the majority of patients present with locally advanced or metastatic disease, and are
thus not eligible for surgical resection with curative intent. For patients with resectable cancers,
robust morphological and molecular predictors able to stratify PDAC prognosis are still needed. In fact,
following the classical tumor, nodes, metastasis (TNM) parameters [5,6], few histological features
have been demonstrated of reliable prognostic significance: resection margin status, lymphovascular
invasion, perineural invasion and extranodal extension of nodal metastasis [6–9].
One morphological feature recently suggested as a possible reliable marker of poor prognosis in
PDAC is tumor budding (TB). It is defined as the presence of a single cell or cell clusters composed of
up to 5 neoplastic cells at the infiltrative front of the tumor, and is an indicator of cancer invasiveness
(Figure 1) [10,11]. This histological parameter has been well studied in colorectal cancer, but its
independent prognostic significance has also been demonstrated for other cancer types [10–16].
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2. Results
2.1. Search Results
Altogether, 131 non-duplicated articles were identified through the literature search. After excluding
100 articles based on title/abstract review, 31 articles were retrieved for full text review and, following the
application of the inclusion criteria, six unique articles were considered as eligible for the meta-analysis
(Figure S1) [20–25].
2.2. Study and Patient Characteristics
Almost all cases of PDAC in the selected manuscripts showed the presence of tumor budding,
thus the authors distinguished patients with high grade-TB vs. low grade-TB. The grade of TB was
established based on the number of tumor buds (e.g., high grade-TB in case of at least 10 buds
per high power field, Table S1). Due to the modality of TB assessment in such manuscripts and
since meta-analyses have to reflect the primary studies, we analyzed the prognostic significance
of high grade-TB vs. low grade-TB in PDAC. Altogether, the studies followed-up 613 patients,
251 (40.9%) of which had high grade-TB. All the selected studies were published in the last 5 years.
They involved distinct cohorts of patients covering almost all continents (Asia, America, Europe and
Africa). The median Newcastle-Ottawa Scale (NOS) score was 7 points (range: 6–8), with no manuscript
considered as at high risk of bias (Tables S1 and S2). Two studies reported raw data only (e.g., number of
deaths) [22,24] whilst in the 4 studies reporting adjusted analyses, the median number of confounders
considered in the multivariate analysis was 4 (Tables S1 and S3) [20,21,23,25]. There was no statistically
significant difference between high grade-TB and low grade-TB groups of patients regarding presence
of lymph node metastasis or pathologic T stage.
2.3. Association between High Grade vs. Low Grade Tumor Budding and Survival
The outcomes analyzed in this meta-analysis were those reported in at least three studies:
they were all-cause mortality (both RR and HR were provided) and risk of recurrence (HR only).
2.3.1. All-Cause Mortality (ACM)
Pooling data from five studies [20–24], there was an increased RR of ACM in patients with
high grade-TB, which was statistically significant (RR, 1.46; 95% CI, 1.13–1.88, p = 0.004, I2 = 76%)
(Table 1, Figure 2A). In four studies reporting adjusted data from multivariate analysis [20,21,23,25],
high grade-TB carried a significantly higher HR of ACM compared to low grade-TB, increasing its
statistical significance (HR, 2.65; 95% CI, 1.79–3.91; p < 0.0001; I2 = 31%) (Table 1, Figure 2B).
Table 1. Risk Ratio and Hazard Ratio for survival indexes of PDAC patients based on high grade-TB
vs. low grade TB status.
Parameter N Studies Risk Ratio(95% CI) p-Value
Heterogeneity
(I2%); Tau2
Egger Test
(p-Value)
ACM 5 1.46(1.13–1.88) 0.004 76%; 0.06 3.61 (0.08)
Parameter N Cohorts Hazard Ratio(95% CI) p-Value
Heterogeneity
(I2%); Tau2
Egger Test
(p-Value)
ACM 4 2.65(1.79–3.91) <0.0001 31%; 0.05 1.85 (0.29)
Parameter N Cohorts Risk Ratio(95% CI) p-Value
Heterogeneity
(I2%); Tau2
Egger Test
(p-Value)
ROR 3 1.61(1.05–2.47) 0.007 85%; 0.11 4.13 (0.09)
Abbreviations: PDAC: pancreatic ductal adenocarcinoma; TB: tumor budding; ACM: all-cause mortality; ROR: risk
of recurrence; CI: confidence intervals.
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2.3.2. Risk of Recurrence (ROR)
Pooling data from three studies [21–23], the presence of high grade-TB increased the RR of ROR
with statistical significance (RR, 1.61; 95% CI, 1.05–2.47, p = 0.03, I2 = 85%) (Table 1, Figure S2).
2.4. Publication Bias and Meta-Regression Analyses
There was no risk of publication bias for all the analyzed indexes: RR of ACM (Egger’s test,
3.61 ± 1.41, p = 0.08), HR for ACM (Egger’s test, 1.85 ± 1.30; p = 0.29) and RR for ROR (Egger’s test,
4.13 ± 0.59, p = 0.09). There was high heteroge eity for RR of ACM and of ROR. However, since high
heteroge eity w s n longer r ported once one outlier study was r moved [20], appearing to be the
main moderator of such heterogeneity, a meta-regression analyses were not performed.
2.5. Focus on Epithelial to Mesenchymal Transition
Using a systematic review-based approach, we found six different manuscripts that
simultaneously analyzed TB and EMT in pancreatic ductal adenocarcinoma [20,22,26–29]. Their main
findings have been summarized in Table 2. In all these manuscripts, we found specific expression
patterns of EMT-associated markers, indicating that EMT is a central process in determining the
presence of TB. Indeed, some studies showed an increased expression of mesenchymal markers such
as vimentin [20,29], ZEB1 and ZEB2 [27] in TB cells, whereas other studies indicated a reduced or focal
expression of epithelial markers, like E-cadherin [27–29], cytokeratin [22] and p63 [26].
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Table 2. Studies that analysed EMT and TB in pancreatic ductal adenocarcinoma, with their
main findings.
References EMT and Other Important Variables Main Findings
Chouat, 2018 [20] Cytokeratin (AE1/AE3) and vimentin
(IHC)
High grade-TB was significantly associated with an
increased vimentin expression (p = 0.002).
Galván, 2015 [27] E-cadherin, β-catenin, SNAIL1, ZEB1,
ZEB2, N-cadherin, TWIST1 (IHC and
mRNA-ISH)
TB cells showed increased levels of ZEB1 (p < 0.0001)
and ZEB2 (p = 0.0119) and reduced E-cadherin (p <
0.0001) and β-catenin (p < 0.0001) expression
compared with the main tumor.
Kohler, 2015 [28] Cytokeratin (AE1/AE3), E-cadherin,
β-catenin, vimentin (IHC)
TB cells showed reduced E-cadherin expression
compared with the main tumor. E-cadherin and
β-catenin showed reduced expression in the tumor
periphery than in the tumor center (p < 0.050).
Lapshyn, 2016 [29] E-cadherin, β-catenin, vimentin (IHC),
morphology of cancer-associated
fibroblasts
Mesenterico-portal venous tumor infiltration was
significantly associated with loss of E-cadherin in
tumor buds (p = 0.020), increased vimentin
expression (p = 0.03) and activated cancer-associated
fibroblasts morphology.
Liu, 2017 [22] Cytokeratin (AE1/AE3) (IHC)
Expression of cytokeratin in tumor budding was
significantly lower than in primary tumor (p = 0.001).
Wartenberg, 2018
[26]
p63 and “immune-cell” markers
Three PDAC subtypes were identified: the one with
the highest grade of TB showed focal p63 expression,
frequent CDKN2A and SMAD4 mutations, a reduced
presence of T and B cells, was enriched in FOXP3
regulatory T cells, and has the worst outcome.
Abbreviations: IHC: immunohistochemistry; ISH: in situ hybridization.
3. Discussion
In this manuscript regarding the prognostic role of TB in PDAC, we found a statistically significant
association between the presence of a high grade-TB and an increased risk of mortality and/or
recurrence of disease. These findings appear reliable, also considering that the association of high
grade-TB and risk of mortality has been confirmed using multivariable analyses data. The independent
prognostic value of high grade-TB was confirmed also observing that both patients with or without
high grade-TB showed no significant differences either in terms of presence of lymph node metastasis
or of pathologic T stage.
The low inclusion rate (4.6%) of papers after screening of the literature underlines the rigorous
method applied for selection of manuscripts. In a meta-analysis, the inclusion rate of manuscripts after
screening with the selected search strategy can vary greatly for a number of reasons. A low inclusion
rate can occur when using a wide and all- encompassing search strategy to find all the papers on a
specific topic, coupled with very strict criteria for paper selection. In our meta-analysis, very specific
and strict criteria were applied, including: (i) presence of a clear comparison of prognostic factors
between high grade-tumor budding (TB) vs. low grade-TB, and (ii) presence of histological diagnosis
of PDAC with clear microscopic demonstration of TB among other criteria. Thus, the low inclusion
rate indicates the high-quality search strategy for paper adherence and selection.
To further corroborate our results, no risk of publication bias emerged from all the analyzed
indexes. In the second part of this study, we performed a systematic review to clarify the biological
role of EMT in PDAC, and found that EMT plays a central role in PDAC with high grade-TB.
Since TB has shown a significant prognostic value in PDAC, it is also important to analyze the
modalities to detect this morphological parameter during routine histological analyses. O’Connor
and colleagues have compared the use of standard hematoxylin/eosin (H&E) staining vs. cytokeratin,
reporting that the assessment of TB with H&E is reliable and can be only slightly improved by coupling
it with immunohistochemical analysis. This specific insight demonstrates that TB can be easily
assessed on routine histological sections and without additional exams, highlighting the feasibility of
documenting TB on standard pathology reports. Notably, the recently proposed ITBCC method for TB
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scoring suggests the use of H&E sections. This is a standardized and well-designed scoring system,
based on a Consensus Conference and validated for TB scoring in PDAC [30]. This scoring system
is easily reproducible, designates assessing TB in the densest budding area at ×20 magnification
(one hot-spot, 0.785 mm2), and subgroups cases into four categories: BD0: no buds; BD1: one to
four buds; BD2: five to nine buds; and BD3: ≥10 buds. Its application can facilitate TB reporting in
diagnostics and in the microscopic description of routine histological exams.
We also found that TB is a morphological aspect intimately associated with EMT, which is a
process of biological changes that permits to epithelial cells to acquire the so-called “mesenchymal
phenotype” [31]. This phenotype leads to a reorganization of cytoskeletal and cell-surface proteins,
leading to increased invasiveness and migratory capacities and to an acquisition of elevated resistance
to apoptosis; it is also characterized by loss of cell polarity, down-regulation of E-cadherin and
acquisition of mesenchymal markers and related transcription factors (e.g., Vimentin, Twist1, Snail2,
ZEB1, ZEB2) [31–33]. All six manuscripts we identified through a systematic review on this specific
topic showed statistically significant data indicating a clear association between the activation of
EMT and the presence of high grade-TB in PDAC (Table 2). Indeed, while PDAC with high grade-TB
demonstrated an increased expression of mesenchymal markers such as vimentin [20,29], ZEB1 and
ZEB2 [27], PDAC with low grade-TB showed a reduced or focal expression of epithelial markers,
like E-cadherin [27–29], cytokeratin [22] and p63 [26]. In particular, the EMT markers most used in this
context are Cytokeratin AE1/AE3 and E-Cadherin as epithelial markers and Vimentin as mesenchymal
markers. EMT and TB are also strongly associated in other tumor types [34–37]: this indicates that
TB is the morphological manifestation of EMT, and that EMT is an important biological mechanism
shared by those tumors that invade the surrounding tissue through single cells or small cell clusters.
We demonstrated that high grade-TB can help in stratifying PDAC prognosis. Of interest,
Wartenberg and colleagues generated new insights on this topic in a recent manuscript, coupling the
analysis of histological parameters (including TB) with their molecular profiling and with the analysis
of the types of tumor-associated inflammatory cells [26]. Three PDAC subtypes were identified,
where the one with the highest grade of TB showed the worst outcome. This PDAC subtype, called
“immune-escape” by the authors, presented reduced infiltration of T and B cells, was enriched in
FOXP3 regulatory T cells, and harboured frequent CDKN2A and SMAD4 mutations. Although further
studies are needed to confirm the reliability of this PDAC categorization, the integration of the most
important morphological parameters with immunological and molecular data may represent a key
element to reach a better stratification of PDAC prognosis. Based on the results of the present study,
TB should be taken into account in all these different but converging aspects.
4. Materials and Methods
This systematic review adhered to the Meta-analyses Of Observational Studies in Epidemiology
(MOOSE) guidelines and Preferred Reporting Items for Systematic Reviews and Meta-Analyses
(PRISMA) statement, following a predetermined protocol [38,39].
4.1. Inclusion and Exclusion Criteria
Studies were eligible for inclusion upon meeting the following criteria: (1) a prospective cohort or
retrospective study design; (2) contained a comparison of prognostic factors between high grade-TB
vs. low grade-TB; (3) contained histological diagnosis of PDAC with clear microscopic demonstration
of TB; (4) contained data about mortality/recurrence of disease; (5) were published in a peer review
journal or published abstract. We considered articles in any language. Exclusion criteria were: (1)
no presence of PDAC, (2) no clear microscopic demonstration of TB, (3) no data about prognostic
parameters in the title/abstract, (4) no comparison between high grade-TB vs. low grade-Tb patients,
and (5) in vitro or animal studies.
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4.2. Data Sources and Literature Search Strategy
Two investigators (R.T.L., C.L.) independently searched PubMed, Embase and SCOPUS until
30 September 2018. The search terms used in PubMed included combinations of the following
keywords: (“pancreas” OR “pancreatic” OR “PDAC”) AND (“budding” OR “sprouting” OR “bud” OR
“buds”) AND (“mortality” OR “mortalities” OR “fatality” OR “fatalities” OR “death*” OR “survival”
OR “recurrence” OR “hazard ratio” OR “HR” OR “relative risk” OR “RR” OR “prognosis” OR
“progression”). A similar research was made in SCOPUS. We considered the reference lists of all
included articles and of previous related reviews.
4.3. Study Selection
Following the searches as outlined above, after removal of duplicates, two independent reviewers
(A.N., N.V.) screened titles and abstracts of all potentially eligible articles. The two authors applied the
eligibility criteria, considered the full texts, and a final list of included articles was reached through
consensus with a third author (C.L.).
4.4. Data Extraction
Two authors were involved in data extraction in a standardized Microsoft Excel database.
Specifically, one author (R.T.L.) extracted data from the included articles and a second independent
author (C.L.) validated the data. For each article, we extracted information about authors, year of
publication, country, exclusion criteria, methods of TB assessment, number of participants and gender,
age, pathologic tumor stage, presence of lymph node metastasis, number of adjustments in survival
analyses and duration of follow-up.
4.5. Outcomes
The primary outcomes were number of deaths and number of recurrences after treatment during
the follow-up period in patients with high grade-TB vs. low grade-TB. Secondary outcomes were
hazard ratios, adjusted for the maximum number of confounders available, regarding the same
outcomes, taking those with low grade-TB as reference. A meta-analysis was conducted only in case of
at least 3 studies per outcome.
4.6. Assessment of Study Quality
We used the Newcastle-Ottawa Scale (NOS) to evaluate study quality [40]. The NOS provides
an assessment of the methodological quality of observational studies and its content validity and
reliability have been widely assessed [41]. Included studies are assessed on 8 items across three key
areas: selection of the participants, comparability of the participants and outcomes. Two authors
(C.L, N.V.) completed the NOS and each study receives an overall score for methodological quality of
up to 9 points with a score of ≤5 (out of 9) indicating high risk of bias.
4.7. Data Synthesis and Statistical Analysis
All analyses were performed using Comprehensive Meta-Analysis (CMA) 2. In our primary
analyses, pooled risk ratios (RRs) and 95% confidence intervals (CIs) of risk of mortality and of
recurrence between high grade-TB vs. low grade-TB were calculated using DerSimonian-Laird
random-effects models [42]. In secondary analyses, pooled hazard ratios (HRs) with 95% CIs adjusted
for the maximum number of covariates available in the articles, were also calculated for providing
additional information if the relationship between TB status and outcomes was influenced by potential
confounders. Heterogeneity across studies was assessed by the I2 metric and chi square statistics [43].
In presence of significant heterogeneity (p < 0.05) after removing outlier studies, we planned to
conduct a series of meta-regression analyses according to TB status and each of prognostic parameters
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considered. Finally, we investigated publication bias for our primary meta-analysis with a visual
inspection of funnel plots coupled with Egger bias test [44].
4.8. Focus on Epithelial-to-Mesenchymal Transition with a Systematic Review-Based Approach
We modified the search strategy originally used for this meta-analysis to find all manuscripts
investigating simultaneously TB and EMT-associated markers/parameters in PDAC. The search terms
used in PubMed included combinations of the following keywords: (“pancreas” OR “pancreatic” OR
“PDAC”) AND (“budding” OR “sprouting” OR “bud” OR “buds”) AND (“EMT” or “epithelial to
mesenchymal”). A similar research was made in Embase and in SCOPUS. We considered the reference
lists of all included articles and of previous related reviews.
5. Conclusions
High-grade TB has a potentially high clinical significance for the prognostic stratification of
PDAC. Furthermore, TB shows a clear association with the process of EMT. The integration of the most
important morphological parameters with immunological and molecular data may represent a key
element to reach a better stratification of PDAC prognosis and to design more effective therapeutic
strategies. The results of our study indicate that TB should be conveyed in pathology reports and
taken into account by future oncologic staging systems.
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